• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

  • About
    • General Information
    • Disease Research
    • Training & Outreach
    • Events
    • Careers
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • News Releases
    • Publications
    • On Your Health
    • Bodywork
  • Patients
    • Anti Aging Study
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Disease
    • Osteoarthritis
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Ways to Give
    • Tax Credit
    • Planned Giving
    • Contact Philanthropy
Home - Development News - OMRF drug wins national award

OMRF drug wins national award

May 15, 2009

A drug based on discoveries made at OMRF was honored today at the National Press Club in Washington, DC.

Each year, the National Organization for Rare Disorders honors individuals and companies for outstanding contributions toward improving the lives of people affected by rare diseases. This year, the group recognized Ceprotin, developed from the work of OMRF’s Charles Esmon, Ph.D., and Naomi Esmon, Ph.D.

Manufactured by Baxter Pharmaceuticals, Ceprotin combats a genetic deficiency of protein C. Left untreated, the deficiency causes blood clots that lead to amputations and ultimately death.

“It’s nice that this came to fruition,” said Charles Esmon, who holds the Lloyd Noble Chair in Cardiovascular Biology at OMRF. “We’re glad that Ceprotin has received this recognition, but we’re just happy knowing that it’s out there and available for people dealing with this genetic disorder.”

Ceprotin was the first drug approved by the European Union’s joint licensing protocol. In 2007, it received marketing in the U.S. from the Food and Drug Administration.

Genetic protein C deficiency affects about 1 in 300 people, according to Naomi Esmon. Insufficient protein C levels are first seen as blood clots in the blood vessels of the skin, eyes, brain and kidneys, but can occur anywhere in the body where blood flows.

“Without this drug, babies with protein C deficiency would die within the first week of life,” she said.

 

Filed Under: Development News, News Tagged With: Charles, Esmon, scientist-news

Before Footer

Equal Opportunity Employer

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Ethics Point
  • Intranet
Facebook Twitter Instagram Linkedin

Subscribe to OMRF News
  • Contact
  • Careers
  • Donor Privacy
  • Ethics Point
  • Intranet
OMRF Logo
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13th St.
Oklahoma City, OK 73104
(405) 271-6673
Charity navigatorUnited WayTop Workplace